Flexilev included in the pharmaceutical benefits program from 2016-05-21!
The Dental and Pharmaceutical Benefits Agency (TLV) decided on 20 May 2016 to include Flexilev in the subsidized medicines with the following conditions and restrictions:
“Limitation of the subsidization: Reimbursed only for patients with advanced Parkinson’s disease for whom conventional tablet treatment with levodopa is no longer enough to control motor fluctuations, and for whom only pump delivery of levodopa-carbidopa gel or apomorphine is possible treatment options or when these are inappropriate. ”
Furthermore TLV writes: “The company should clearly inform about the above in all its marketing and other information about the medicine.”
We are pleased, of course, be able to offer our treatment to this group of patients where there are currently few treatment options left. We now inform the the medical community about this decision in accordance with the above restriction and look confidently forward to start marketing our product.